Hughes, Daniel Johnathan
Josephides, Eleni
O’Shea, Robert
Manickavasagar, Thubeena
Horst, Carolyn
Hunter, Sarah
Tanière, Philippe
Nonaka, Daisuke
Van Hemelrijck, Mieke
Spicer, James
Goh, Vicky
Bille, Andrea
Karapanagiotou, Eleni
Cook, Gary J. R. http://orcid.org/0000-0003-2641-7632
Funding for this research was provided by:
Merck Sharp and Dohme
Wellcome Trust (WT 203148/Z/16/Z)
Cancer Research UK (C1519/A28682)
Article History
Received: 19 October 2023
Revised: 24 December 2023
Accepted: 17 January 2024
First Online: 22 February 2024
Declarations
:
: The scientific guarantor of this publication is Professor Gary Cook (GJRC).
: DJH has received honoraria/speaker fees from Pfizer and Bristol Myers Squibb, transport/accommodation grants from Bristol Myers Squibb, Roche and NanoMab Technology and research funding via institute from NanoMab Technology, and is an executive committee member of the Association of Cancer Physicians (UK). EK has received research funding via institute from Merck, Sharp & Dohme (MSD). GJRC has received research support from NanoMab Technology, Theragnostics and Serac Healthcare, and provides consultancy for GE Healthcare, NanoMab Technology, Amgen, Blue Earth Diagnostics and Full-Life Technologies. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: One of the authors has significant statistical expertise. No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study as per the institutional review board.
: The study underwent ethics review and was approved by UK Research Ethics Committee (UK IRAS 228790) and within the previously described Guy’s Cancer Cohort framework (ref: 18/NW/0297).
: No study subjects have been previously reported to the best of the authors’ knowledge.
: • This is a retrospective observational study performed at one institution involving individual subjects from several referring centres.